List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 113 studies with search of:   "Benzoates"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
Condition: Hepatic Encephalopathy
Interventions: Drug: sodium phenylacetate and sodium benzoate injection 10% / 10%;   Drug: sodium phenylacetate and sodium benzoate injection 10% / 10%;   Drug: placebo solution (10% dextrose)
2 Completed Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders
Condition: Amino Acid Metabolism, Inborn Errors
Interventions: Drug: Sodium Benzoate;   Drug: Sodium Phenylacetate;   Drug: Sodium Phenylbutyrate;   Behavioral: Dietary Intervention
3 Completed Study to Test a Marketed Drug (MK0462) in the Early Treatment of Acute Migraine
Condition: Migraine
Interventions: Drug: rizatriptan benzoate;   Drug: Comparator: placebo (unspecified)
4 Not yet recruiting A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis
Condition: Migraine
Interventions: Drug: rizatriptan benzoate;   Drug: Comparator: placebo
5 Active, not recruiting Drug Study in Pediatric Subjects With Migraines
Condition: Migraine Disorders
Interventions: Drug: rizatriptan benzoate;   Drug: Comparator : placebo (unspecified)
6 Active, not recruiting MK0974 Long Term Safety Study
Condition: Migraine
Interventions: Drug: MK0974 / Duration of Treatment: 1 Years;   Drug: Comparator: rizatriptan benzoate / Duration of Treatment: 1 Years
7 Completed Study to Test an Approved Product in the Early Treatment of Migraine
Condition: Migraine
Interventions: Drug: MK0462, rizatriptan benzoate / Duration of Treatment: 1day;   Drug: Comparator: placebo / Duration of Treatment: 1 day
8 Completed Study to Test a Marketed Drug in the Treatment of Menstrual Migraine
Condition: Migraine
Interventions: Drug: MK0462, rizatriptan benzoate / Duration of Treatment -1 day;   Drug: Comparator: placebo / Duration of Treatment - 1 day
9 Completed Study to Test a Marketed Drug in the Treatment of Menstrual Migraine
Condition: Migraine
Interventions: Drug: MK0462, rizatriptan benzoate / Duration of Treatment -1day;   Drug: Comparator: placebo / Duration of Treatment - 1 day
10 Completed Study to Test an Approved Product in the Early Treatment of Migraine
Condition: Migraine
Interventions: Drug: MK0462, rizatriptan benzoate / Duration of Treatment: 1day;   Drug: Comparator: placebo / Duration of Treatment: 1 day
11 Completed Study to Test a Marketed Product in the Treatment of Migraine-Associated Nausea
Condition: Migraine
Interventions: Drug: MK0462, rizatriptan benzoate / Duration of Treatment One (1) Day;   Drug: Comparator: placebo / Duration of Treatment One (1) Day
12 Recruiting Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension
Condition: Hypertension
Interventions: Drug: telmisartan;   Drug: telmisartan + hydrochlorothiazide
13 Completed Non-Responder Study to Telmisartan 40 mg
Condition: Hypertension
Interventions: Drug: Telmisartan 40 mg/HCTZ 12.5 mg;   Drug: Telmisartan 40 mg
14 Completed Open-Label Follow-up Trial of Fixed Dose Combination of Telmisartan 80 mg + Hydrochlorothiazide 25 mg
Condition: Hypertension
Intervention: Drug: telmisartan 80 mg + hydrochlorothiazide 25 mg
15 Completed 3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension
Condition: Hypertension
Interventions: Drug: Telmisartan;   Drug: Hydrochlorothiazide;   Drug: Telmisartan + Hydrochlorothiazide
16 Recruiting 26-Week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension
Condition: Hypertension
Interventions: Drug: fixed-dose combination of telmisartan 40mg+amlodipine 10mg;   Drug: fixed-dose combination of telmisartan 80mg+amlodipine10mg
17 Completed Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension
Condition: Hypertension
Interventions: Drug: Telmisartan 40 mg/HCTZ 12.5 mg;   Drug: Telmisartan 40 mg;   Drug: Telmisartan 80 mg/HCTZ 12.5 mg
18 Completed Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5
Condition: Hypertension
Interventions: Drug: Fixed dose combination telmisartan 80 mg + HCTZ 25 mg;   Drug: Fixed dose combination telmisartan 80 mg + HCTZ 12.5 mg
19 Completed A Randomized, Double-Blind, Parallel-Group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate Hypertension
Condition: Hypertension
Interventions: Drug: telmisartan 40mg / hydrochlorothiazide 12.5mg;   Drug: osartan 50mg / hydrochlorothiazide 12.5mg
20 Completed Phase II Study of RR110 in Patients With Active Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: RR110 (Tamibarotene);   Drug: RR110 (Tamibarotene)

Previous Page Studies Shown (1-20) Next (21-40)
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services